nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydralazine—P4HA1—Vitamin C—prostate cancer	0.427	0.742	CbGbCtD
Hydralazine—CYP3A4—prostate cancer	0.17	1	CbGaD
Hydralazine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0306	0.0533	CbGbCtD
Hydralazine—CYP3A4—Bicalutamide—prostate cancer	0.0161	0.028	CbGbCtD
Hydralazine—CYP3A4—Estramustine—prostate cancer	0.015	0.026	CbGbCtD
Hydralazine—CYP3A4—Flutamide—prostate cancer	0.0133	0.0232	CbGbCtD
Hydralazine—CYP3A4—Abiraterone—prostate cancer	0.0133	0.0232	CbGbCtD
Hydralazine—CYP3A4—Cabazitaxel—prostate cancer	0.00986	0.0172	CbGbCtD
Hydralazine—CYP3A4—Estrone—prostate cancer	0.00964	0.0168	CbGbCtD
Hydralazine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00859	0.0149	CbGbCtD
Hydralazine—RYR2—prostate gland—prostate cancer	0.00692	0.121	CbGeAlD
Hydralazine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00631	0.011	CbGbCtD
Hydralazine—RYR2—seminal vesicle—prostate cancer	0.00585	0.103	CbGeAlD
Hydralazine—CYP3A4—Mitoxantrone—prostate cancer	0.00573	0.00997	CbGbCtD
Hydralazine—CYP3A4—Estradiol—prostate cancer	0.00554	0.00963	CbGbCtD
Hydralazine—CYP3A4—Prednisone—prostate cancer	0.00476	0.00828	CbGbCtD
Hydralazine—RYR2—urethra—prostate cancer	0.00463	0.0812	CbGeAlD
Hydralazine—AOC3—prostate gland—prostate cancer	0.00417	0.073	CbGeAlD
Hydralazine—CYP3A4—Etoposide—prostate cancer	0.00361	0.00629	CbGbCtD
Hydralazine—AOC3—seminal vesicle—prostate cancer	0.00352	0.0618	CbGeAlD
Hydralazine—P4HA1—prostate gland—prostate cancer	0.00333	0.0584	CbGeAlD
Hydralazine—CYP3A4—Docetaxel—prostate cancer	0.00331	0.00576	CbGbCtD
Hydralazine—RYR2—testis—prostate cancer	0.00305	0.0534	CbGeAlD
Hydralazine—AOC3—renal system—prostate cancer	0.00284	0.0498	CbGeAlD
Hydralazine—P4HA1—seminal vesicle—prostate cancer	0.00282	0.0494	CbGeAlD
Hydralazine—AOC3—urethra—prostate cancer	0.00279	0.0489	CbGeAlD
Hydralazine—CYP3A4—Doxorubicin—prostate cancer	0.00247	0.00429	CbGbCtD
Hydralazine—CYP3A4—urine—prostate cancer	0.00246	0.0431	CbGeAlD
Hydralazine—P4HA1—renal system—prostate cancer	0.00227	0.0398	CbGeAlD
Hydralazine—P4HA1—urethra—prostate cancer	0.00223	0.0391	CbGeAlD
Hydralazine—AOC3—bone marrow—prostate cancer	0.00215	0.0376	CbGeAlD
Hydralazine—AOC3—testis—prostate cancer	0.00183	0.0322	CbGeAlD
Hydralazine—P4HA1—bone marrow—prostate cancer	0.00172	0.0301	CbGeAlD
Hydralazine—P4HA1—testis—prostate cancer	0.00147	0.0257	CbGeAlD
Hydralazine—AOC3—lymph node—prostate cancer	0.00133	0.0233	CbGeAlD
Hydralazine—P4HA1—lymph node—prostate cancer	0.00106	0.0186	CbGeAlD
Hydralazine—CYP3A4—renal system—prostate cancer	0.000602	0.0105	CbGeAlD
Hydralazine—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—prostate cancer	0.000148	0.00276	CbGpPWpGaD
Hydralazine—CYP3A4—Xenobiotics—CYP2A6—prostate cancer	0.000145	0.00272	CbGpPWpGaD
Hydralazine—CYP3A4—Tamoxifen metabolism—CYP2C19—prostate cancer	0.000145	0.00271	CbGpPWpGaD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP3A43—prostate cancer	0.000144	0.00269	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—NCOA1—prostate cancer	0.000143	0.00267	CbGpPWpGaD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP3A43—prostate cancer	0.000142	0.00265	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTCD—prostate cancer	0.00014	0.00262	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTK1—prostate cancer	0.00014	0.00262	CbGpPWpGaD
Hydralazine—CYP3A4—Tamoxifen metabolism—CYP2A6—prostate cancer	0.00014	0.00261	CbGpPWpGaD
Hydralazine—CYP3A4—Tryptophan metabolism—CYP7B1—prostate cancer	0.000138	0.00258	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—prostate cancer	0.000136	0.00255	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—RXRA—prostate cancer	0.000136	0.00254	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—SULT1A1—prostate cancer	0.000135	0.00252	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—NQO1—prostate cancer	0.000133	0.00249	CbGpPWpGaD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG5—prostate cancer	0.000128	0.0024	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—CYP1B1—prostate cancer	0.000127	0.00238	CbGpPWpGaD
Hydralazine—CYP3A4—Xenobiotics—CYP2E1—prostate cancer	0.000124	0.00231	CbGpPWpGaD
Hydralazine—CYP3A4—Tamoxifen metabolism—CYP2E1—prostate cancer	0.000119	0.00222	CbGpPWpGaD
Hydralazine—CYP3A4—Aflatoxin activation and detoxification—GGT1—prostate cancer	0.000118	0.00221	CbGpPWpGaD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A43—prostate cancer	0.000116	0.00218	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—SULT2A1—prostate cancer	0.000116	0.00217	CbGpPWpGaD
Hydralazine—CYP3A4—Tamoxifen metabolism—CYP1B1—prostate cancer	0.000113	0.00211	CbGpPWpGaD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP7B1—prostate cancer	0.000112	0.00209	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—COMT—prostate cancer	0.000111	0.00208	CbGpPWpGaD
Hydralazine—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—prostate cancer	0.000111	0.00207	CbGpPWpGaD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP7B1—prostate cancer	0.00011	0.00206	CbGpPWpGaD
Hydralazine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—prostate cancer	0.00011	0.00205	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—IL6—prostate cancer	0.000109	0.00205	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL6—prostate cancer	0.000109	0.00204	CbGpPWpGaD
Hydralazine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—prostate cancer	0.000106	0.00198	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—PPARA—prostate cancer	0.000104	0.00194	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C19—prostate cancer	0.000103	0.00193	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—GSTM1—prostate cancer	0.000102	0.0019	CbGpPWpGaD
Hydralazine—Decreased appetite—Mitoxantrone—prostate cancer	0.0001	0.000691	CcSEcCtD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—prostate cancer	9.97e-05	0.00187	CbGpPWpGaD
Hydralazine—Vomiting—Goserelin—prostate cancer	9.92e-05	0.000684	CcSEcCtD
Hydralazine—Discomfort—Etoposide—prostate cancer	9.88e-05	0.000681	CcSEcCtD
Hydralazine—Constipation—Mitoxantrone—prostate cancer	9.85e-05	0.000679	CcSEcCtD
Hydralazine—Rash—Goserelin—prostate cancer	9.84e-05	0.000678	CcSEcCtD
Hydralazine—Dermatitis—Goserelin—prostate cancer	9.83e-05	0.000678	CcSEcCtD
Hydralazine—Vomiting—Conjugated Estrogens—prostate cancer	9.82e-05	0.000677	CcSEcCtD
Hydralazine—Urticaria—Estradiol—prostate cancer	9.82e-05	0.000677	CcSEcCtD
Hydralazine—Body temperature increased—Estradiol—prostate cancer	9.78e-05	0.000674	CcSEcCtD
Hydralazine—Headache—Goserelin—prostate cancer	9.77e-05	0.000674	CcSEcCtD
Hydralazine—Rash—Conjugated Estrogens—prostate cancer	9.74e-05	0.000672	CcSEcCtD
Hydralazine—Chills—Capecitabine—prostate cancer	9.74e-05	0.000672	CcSEcCtD
Hydralazine—Dermatitis—Conjugated Estrogens—prostate cancer	9.73e-05	0.000671	CcSEcCtD
Hydralazine—Headache—Conjugated Estrogens—prostate cancer	9.68e-05	0.000667	CcSEcCtD
Hydralazine—CYP3A4—Estrogen metabolism—CYP1A1—prostate cancer	9.65e-05	0.00181	CbGpPWpGaD
Hydralazine—Hallucination—Prednisone—prostate cancer	9.62e-05	0.000663	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP3A5—prostate cancer	9.58e-05	0.00179	CbGpPWpGaD
Hydralazine—Feeling abnormal—Mitoxantrone—prostate cancer	9.5e-05	0.000655	CcSEcCtD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP3A5—prostate cancer	9.46e-05	0.00177	CbGpPWpGaD
Hydralazine—Thrombocytopenia—Etoposide—prostate cancer	9.38e-05	0.000647	CcSEcCtD
Hydralazine—Muscle spasms—Docetaxel—prostate cancer	9.38e-05	0.000647	CcSEcCtD
Hydralazine—Tachycardia—Etoposide—prostate cancer	9.35e-05	0.000645	CcSEcCtD
Hydralazine—Eosinophilia—Epirubicin—prostate cancer	9.35e-05	0.000645	CcSEcCtD
Hydralazine—CYP3A4—Tryptophan metabolism—CYP2C18—prostate cancer	9.33e-05	0.00175	CbGpPWpGaD
Hydralazine—Nausea—Goserelin—prostate cancer	9.27e-05	0.000639	CcSEcCtD
Hydralazine—CYP3A4—Irinotecan Pathway—APC—prostate cancer	9.25e-05	0.00173	CbGpPWpGaD
Hydralazine—Angina pectoris—Epirubicin—prostate cancer	9.2e-05	0.000635	CcSEcCtD
Hydralazine—Nausea—Conjugated Estrogens—prostate cancer	9.18e-05	0.000633	CcSEcCtD
Hydralazine—Urticaria—Mitoxantrone—prostate cancer	9.15e-05	0.000631	CcSEcCtD
Hydralazine—Anorexia—Etoposide—prostate cancer	9.14e-05	0.00063	CcSEcCtD
Hydralazine—Hypersensitivity—Estradiol—prostate cancer	9.11e-05	0.000628	CcSEcCtD
Hydralazine—Body temperature increased—Mitoxantrone—prostate cancer	9.11e-05	0.000628	CcSEcCtD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA2—prostate cancer	9.1e-05	0.0017	CbGpPWpGaD
Hydralazine—Muscle spasms—Capecitabine—prostate cancer	9.08e-05	0.000626	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP7B1—prostate cancer	9.05e-05	0.00169	CbGpPWpGaD
Hydralazine—Anaemia—Docetaxel—prostate cancer	9.02e-05	0.000622	CcSEcCtD
Hydralazine—Flushing—Prednisone—prostate cancer	8.97e-05	0.000619	CcSEcCtD
Hydralazine—Pancytopenia—Epirubicin—prostate cancer	8.97e-05	0.000619	CcSEcCtD
Hydralazine—Hypotension—Etoposide—prostate cancer	8.96e-05	0.000617	CcSEcCtD
Hydralazine—CYP3A4—Xenobiotics—CYP1A1—prostate cancer	8.87e-05	0.00166	CbGpPWpGaD
Hydralazine—Tremor—Capecitabine—prostate cancer	8.85e-05	0.00061	CcSEcCtD
Hydralazine—Dysuria—Epirubicin—prostate cancer	8.83e-05	0.000609	CcSEcCtD
Hydralazine—Neutropenia—Epirubicin—prostate cancer	8.83e-05	0.000609	CcSEcCtD
Hydralazine—Ill-defined disorder—Capecitabine—prostate cancer	8.77e-05	0.000604	CcSEcCtD
Hydralazine—Pruritus—Estradiol—prostate cancer	8.75e-05	0.000603	CcSEcCtD
Hydralazine—Leukopenia—Docetaxel—prostate cancer	8.74e-05	0.000602	CcSEcCtD
Hydralazine—Anaemia—Capecitabine—prostate cancer	8.73e-05	0.000602	CcSEcCtD
Hydralazine—Eosinophilia—Doxorubicin—prostate cancer	8.66e-05	0.000597	CcSEcCtD
Hydralazine—Palpitations—Docetaxel—prostate cancer	8.62e-05	0.000595	CcSEcCtD
Hydralazine—Paraesthesia—Etoposide—prostate cancer	8.61e-05	0.000593	CcSEcCtD
Hydralazine—Weight decreased—Epirubicin—prostate cancer	8.55e-05	0.000589	CcSEcCtD
Hydralazine—Dyspnoea—Etoposide—prostate cancer	8.54e-05	0.000589	CcSEcCtD
Hydralazine—CYP3A4—Tamoxifen metabolism—CYP1A1—prostate cancer	8.53e-05	0.0016	CbGpPWpGaD
Hydralazine—Malaise—Capecitabine—prostate cancer	8.52e-05	0.000588	CcSEcCtD
Hydralazine—Angina pectoris—Doxorubicin—prostate cancer	8.52e-05	0.000587	CcSEcCtD
Hydralazine—Hypersensitivity—Mitoxantrone—prostate cancer	8.49e-05	0.000585	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—TBXAS1—prostate cancer	8.47e-05	0.00158	CbGpPWpGaD
Hydralazine—Diarrhoea—Estradiol—prostate cancer	8.46e-05	0.000583	CcSEcCtD
Hydralazine—Leukopenia—Capecitabine—prostate cancer	8.46e-05	0.000583	CcSEcCtD
Hydralazine—Palpitations—Capecitabine—prostate cancer	8.35e-05	0.000576	CcSEcCtD
Hydralazine—Decreased appetite—Etoposide—prostate cancer	8.33e-05	0.000574	CcSEcCtD
Hydralazine—Arthralgia—Docetaxel—prostate cancer	8.31e-05	0.000573	CcSEcCtD
Hydralazine—Myalgia—Docetaxel—prostate cancer	8.31e-05	0.000573	CcSEcCtD
Hydralazine—Pancytopenia—Doxorubicin—prostate cancer	8.3e-05	0.000572	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Etoposide—prostate cancer	8.27e-05	0.000571	CcSEcCtD
Hydralazine—Neuropathy peripheral—Epirubicin—prostate cancer	8.26e-05	0.000569	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—CREBBP—prostate cancer	8.24e-05	0.00154	CbGpPWpGaD
Hydralazine—Jaundice—Epirubicin—prostate cancer	8.21e-05	0.000566	CcSEcCtD
Hydralazine—Constipation—Etoposide—prostate cancer	8.2e-05	0.000565	CcSEcCtD
Hydralazine—Conjunctivitis—Epirubicin—prostate cancer	8.19e-05	0.000565	CcSEcCtD
Hydralazine—Dizziness—Estradiol—prostate cancer	8.18e-05	0.000564	CcSEcCtD
Hydralazine—Dysuria—Doxorubicin—prostate cancer	8.17e-05	0.000564	CcSEcCtD
Hydralazine—Neutropenia—Doxorubicin—prostate cancer	8.17e-05	0.000564	CcSEcCtD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—prostate cancer	8.08e-05	0.00151	CbGpPWpGaD
Hydralazine—Arthralgia—Capecitabine—prostate cancer	8.04e-05	0.000555	CcSEcCtD
Hydralazine—Myalgia—Capecitabine—prostate cancer	8.04e-05	0.000555	CcSEcCtD
Hydralazine—Haematuria—Epirubicin—prostate cancer	8.03e-05	0.000554	CcSEcCtD
Hydralazine—Anxiety—Capecitabine—prostate cancer	8.02e-05	0.000553	CcSEcCtD
Hydralazine—Oedema—Docetaxel—prostate cancer	7.97e-05	0.000549	CcSEcCtD
Hydralazine—Discomfort—Capecitabine—prostate cancer	7.95e-05	0.000548	CcSEcCtD
Hydralazine—Weight decreased—Doxorubicin—prostate cancer	7.91e-05	0.000545	CcSEcCtD
Hydralazine—Feeling abnormal—Etoposide—prostate cancer	7.9e-05	0.000545	CcSEcCtD
Hydralazine—Diarrhoea—Mitoxantrone—prostate cancer	7.88e-05	0.000544	CcSEcCtD
Hydralazine—Vomiting—Estradiol—prostate cancer	7.86e-05	0.000542	CcSEcCtD
Hydralazine—Agranulocytosis—Epirubicin—prostate cancer	7.86e-05	0.000542	CcSEcCtD
Hydralazine—Ill-defined disorder—Prednisone—prostate cancer	7.81e-05	0.000538	CcSEcCtD
Hydralazine—Thrombocytopenia—Docetaxel—prostate cancer	7.8e-05	0.000538	CcSEcCtD
Hydralazine—Rash—Estradiol—prostate cancer	7.8e-05	0.000538	CcSEcCtD
Hydralazine—Dermatitis—Estradiol—prostate cancer	7.79e-05	0.000537	CcSEcCtD
Hydralazine—Anaemia—Prednisone—prostate cancer	7.78e-05	0.000536	CcSEcCtD
Hydralazine—Tachycardia—Docetaxel—prostate cancer	7.77e-05	0.000536	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A5—prostate cancer	7.77e-05	0.00145	CbGpPWpGaD
Hydralazine—Headache—Estradiol—prostate cancer	7.75e-05	0.000534	CcSEcCtD
Hydralazine—Agitation—Prednisone—prostate cancer	7.73e-05	0.000533	CcSEcCtD
Hydralazine—Oedema—Capecitabine—prostate cancer	7.71e-05	0.000532	CcSEcCtD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA1—prostate cancer	7.67e-05	0.00143	CbGpPWpGaD
Hydralazine—Neuropathy peripheral—Doxorubicin—prostate cancer	7.64e-05	0.000527	CcSEcCtD
Hydralazine—Urticaria—Etoposide—prostate cancer	7.61e-05	0.000525	CcSEcCtD
Hydralazine—Jaundice—Doxorubicin—prostate cancer	7.6e-05	0.000524	CcSEcCtD
Hydralazine—Anorexia—Docetaxel—prostate cancer	7.59e-05	0.000523	CcSEcCtD
Hydralazine—Malaise—Prednisone—prostate cancer	7.59e-05	0.000523	CcSEcCtD
Hydralazine—Body temperature increased—Etoposide—prostate cancer	7.58e-05	0.000522	CcSEcCtD
Hydralazine—Conjunctivitis—Doxorubicin—prostate cancer	7.58e-05	0.000522	CcSEcCtD
Hydralazine—Hepatitis—Epirubicin—prostate cancer	7.56e-05	0.000521	CcSEcCtD
Hydralazine—Thrombocytopenia—Capecitabine—prostate cancer	7.55e-05	0.000521	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—prostate cancer	7.54e-05	0.00141	CbGpPWpGaD
Hydralazine—Tachycardia—Capecitabine—prostate cancer	7.53e-05	0.000519	CcSEcCtD
Hydralazine—Hypoaesthesia—Epirubicin—prostate cancer	7.52e-05	0.000519	CcSEcCtD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—prostate cancer	7.45e-05	0.00139	CbGpPWpGaD
Hydralazine—Hypotension—Docetaxel—prostate cancer	7.44e-05	0.000513	CcSEcCtD
Hydralazine—Haematuria—Doxorubicin—prostate cancer	7.43e-05	0.000512	CcSEcCtD
Hydralazine—Anorexia—Capecitabine—prostate cancer	7.35e-05	0.000507	CcSEcCtD
Hydralazine—Nausea—Estradiol—prostate cancer	7.35e-05	0.000506	CcSEcCtD
Hydralazine—Vomiting—Mitoxantrone—prostate cancer	7.33e-05	0.000505	CcSEcCtD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—prostate cancer	7.29e-05	0.00136	CbGpPWpGaD
Hydralazine—Agranulocytosis—Doxorubicin—prostate cancer	7.27e-05	0.000502	CcSEcCtD
Hydralazine—Rash—Mitoxantrone—prostate cancer	7.27e-05	0.000501	CcSEcCtD
Hydralazine—Dermatitis—Mitoxantrone—prostate cancer	7.26e-05	0.0005	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.26e-05	0.0005	CcSEcCtD
Hydralazine—Headache—Mitoxantrone—prostate cancer	7.22e-05	0.000498	CcSEcCtD
Hydralazine—Hypotension—Capecitabine—prostate cancer	7.21e-05	0.000497	CcSEcCtD
Hydralazine—Myalgia—Prednisone—prostate cancer	7.17e-05	0.000494	CcSEcCtD
Hydralazine—Arthralgia—Prednisone—prostate cancer	7.17e-05	0.000494	CcSEcCtD
Hydralazine—Paraesthesia—Docetaxel—prostate cancer	7.15e-05	0.000493	CcSEcCtD
Hydralazine—Anxiety—Prednisone—prostate cancer	7.14e-05	0.000492	CcSEcCtD
Hydralazine—Dyspnoea—Docetaxel—prostate cancer	7.1e-05	0.00049	CcSEcCtD
Hydralazine—Discomfort—Prednisone—prostate cancer	7.08e-05	0.000488	CcSEcCtD
Hydralazine—Hypersensitivity—Etoposide—prostate cancer	7.06e-05	0.000487	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Capecitabine—prostate cancer	7.03e-05	0.000484	CcSEcCtD
Hydralazine—Flushing—Epirubicin—prostate cancer	7.02e-05	0.000484	CcSEcCtD
Hydralazine—Dyspepsia—Docetaxel—prostate cancer	7.01e-05	0.000483	CcSEcCtD
Hydralazine—Hepatitis—Doxorubicin—prostate cancer	7e-05	0.000482	CcSEcCtD
Hydralazine—Hypoaesthesia—Doxorubicin—prostate cancer	6.96e-05	0.00048	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—UGT2B17—prostate cancer	6.94e-05	0.0013	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—UGT2B15—prostate cancer	6.94e-05	0.0013	CbGpPWpGaD
Hydralazine—Paraesthesia—Capecitabine—prostate cancer	6.92e-05	0.000477	CcSEcCtD
Hydralazine—Decreased appetite—Docetaxel—prostate cancer	6.92e-05	0.000477	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Docetaxel—prostate cancer	6.88e-05	0.000474	CcSEcCtD
Hydralazine—Dyspnoea—Capecitabine—prostate cancer	6.88e-05	0.000474	CcSEcCtD
Hydralazine—Oedema—Prednisone—prostate cancer	6.87e-05	0.000474	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—TBXAS1—prostate cancer	6.86e-05	0.00128	CbGpPWpGaD
Hydralazine—Nausea—Mitoxantrone—prostate cancer	6.84e-05	0.000472	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—UGT2B17—prostate cancer	6.84e-05	0.00128	CbGpPWpGaD
Hydralazine—Constipation—Docetaxel—prostate cancer	6.81e-05	0.00047	CcSEcCtD
Hydralazine—Dyspepsia—Capecitabine—prostate cancer	6.79e-05	0.000468	CcSEcCtD
Hydralazine—Chills—Epirubicin—prostate cancer	6.79e-05	0.000468	CcSEcCtD
Hydralazine—Pruritus—Etoposide—prostate cancer	6.78e-05	0.000468	CcSEcCtD
Hydralazine—Tachycardia—Prednisone—prostate cancer	6.7e-05	0.000462	CcSEcCtD
Hydralazine—Decreased appetite—Capecitabine—prostate cancer	6.7e-05	0.000462	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Capecitabine—prostate cancer	6.66e-05	0.000459	CcSEcCtD
Hydralazine—Constipation—Capecitabine—prostate cancer	6.59e-05	0.000455	CcSEcCtD
Hydralazine—Feeling abnormal—Docetaxel—prostate cancer	6.56e-05	0.000453	CcSEcCtD
Hydralazine—Diarrhoea—Etoposide—prostate cancer	6.56e-05	0.000452	CcSEcCtD
Hydralazine—Anorexia—Prednisone—prostate cancer	6.55e-05	0.000451	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—GSTM3—prostate cancer	6.52e-05	0.00122	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—SULT2B1—prostate cancer	6.52e-05	0.00122	CbGpPWpGaD
Hydralazine—Flushing—Doxorubicin—prostate cancer	6.49e-05	0.000448	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—SULT2B1—prostate cancer	6.43e-05	0.0012	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTM3—prostate cancer	6.43e-05	0.0012	CbGpPWpGaD
Hydralazine—Feeling abnormal—Capecitabine—prostate cancer	6.36e-05	0.000438	CcSEcCtD
Hydralazine—CYP3A4—Tryptophan metabolism—CYP2E1—prostate cancer	6.34e-05	0.00119	CbGpPWpGaD
Hydralazine—Dizziness—Etoposide—prostate cancer	6.34e-05	0.000437	CcSEcCtD
Hydralazine—Muscle spasms—Epirubicin—prostate cancer	6.33e-05	0.000436	CcSEcCtD
Hydralazine—Body temperature increased—Docetaxel—prostate cancer	6.3e-05	0.000434	CcSEcCtD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—prostate cancer	6.29e-05	0.00118	CbGpPWpGaD
Hydralazine—Chills—Doxorubicin—prostate cancer	6.28e-05	0.000433	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Prednisone—prostate cancer	6.26e-05	0.000432	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C19—prostate cancer	6.25e-05	0.00117	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—NAT1—prostate cancer	6.18e-05	0.00116	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP3A43—prostate cancer	6.18e-05	0.00116	CbGpPWpGaD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP2C19—prostate cancer	6.17e-05	0.00115	CbGpPWpGaD
Hydralazine—Paraesthesia—Prednisone—prostate cancer	6.17e-05	0.000425	CcSEcCtD
Hydralazine—Urticaria—Capecitabine—prostate cancer	6.13e-05	0.000422	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—prostate cancer	6.12e-05	0.00114	CbGpPWpGaD
Hydralazine—Ill-defined disorder—Epirubicin—prostate cancer	6.11e-05	0.000421	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP3A43—prostate cancer	6.1e-05	0.00114	CbGpPWpGaD
Hydralazine—Body temperature increased—Capecitabine—prostate cancer	6.1e-05	0.00042	CcSEcCtD
Hydralazine—Vomiting—Etoposide—prostate cancer	6.09e-05	0.00042	CcSEcCtD
Hydralazine—Anaemia—Epirubicin—prostate cancer	6.08e-05	0.000419	CcSEcCtD
Hydralazine—Agitation—Epirubicin—prostate cancer	6.05e-05	0.000417	CcSEcCtD
Hydralazine—Dyspepsia—Prednisone—prostate cancer	6.05e-05	0.000417	CcSEcCtD
Hydralazine—Rash—Etoposide—prostate cancer	6.04e-05	0.000417	CcSEcCtD
Hydralazine—Dermatitis—Etoposide—prostate cancer	6.04e-05	0.000416	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—prostate cancer	6.03e-05	0.00113	CbGpPWpGaD
Hydralazine—CYP3A4—Tryptophan metabolism—CYP1B1—prostate cancer	6.01e-05	0.00112	CbGpPWpGaD
Hydralazine—Headache—Etoposide—prostate cancer	6e-05	0.000414	CcSEcCtD
Hydralazine—Decreased appetite—Prednisone—prostate cancer	5.97e-05	0.000412	CcSEcCtD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—prostate cancer	5.95e-05	0.00111	CbGpPWpGaD
Hydralazine—Malaise—Epirubicin—prostate cancer	5.94e-05	0.000409	CcSEcCtD
Hydralazine—Leukopenia—Epirubicin—prostate cancer	5.89e-05	0.000406	CcSEcCtD
Hydralazine—Constipation—Prednisone—prostate cancer	5.87e-05	0.000405	CcSEcCtD
Hydralazine—Hypersensitivity—Docetaxel—prostate cancer	5.87e-05	0.000405	CcSEcCtD
Hydralazine—Muscle spasms—Doxorubicin—prostate cancer	5.86e-05	0.000404	CcSEcCtD
Hydralazine—Palpitations—Epirubicin—prostate cancer	5.82e-05	0.000401	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—prostate cancer	5.78e-05	0.00108	CbGpPWpGaD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—prostate cancer	5.7e-05	0.00107	CbGpPWpGaD
Hydralazine—Nausea—Etoposide—prostate cancer	5.69e-05	0.000393	CcSEcCtD
Hydralazine—Hypersensitivity—Capecitabine—prostate cancer	5.68e-05	0.000392	CcSEcCtD
Hydralazine—Feeling abnormal—Prednisone—prostate cancer	5.66e-05	0.00039	CcSEcCtD
Hydralazine—CYP3A4—Tryptophan metabolism—CYP19A1—prostate cancer	5.65e-05	0.00106	CbGpPWpGaD
Hydralazine—Ill-defined disorder—Doxorubicin—prostate cancer	5.65e-05	0.00039	CcSEcCtD
Hydralazine—Pruritus—Docetaxel—prostate cancer	5.64e-05	0.000389	CcSEcCtD
Hydralazine—Anaemia—Doxorubicin—prostate cancer	5.63e-05	0.000388	CcSEcCtD
Hydralazine—Myalgia—Epirubicin—prostate cancer	5.6e-05	0.000386	CcSEcCtD
Hydralazine—Arthralgia—Epirubicin—prostate cancer	5.6e-05	0.000386	CcSEcCtD
Hydralazine—Agitation—Doxorubicin—prostate cancer	5.6e-05	0.000386	CcSEcCtD
Hydralazine—Anxiety—Epirubicin—prostate cancer	5.59e-05	0.000385	CcSEcCtD
Hydralazine—Discomfort—Epirubicin—prostate cancer	5.54e-05	0.000382	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA2—prostate cancer	5.5e-05	0.00103	CbGpPWpGaD
Hydralazine—Malaise—Doxorubicin—prostate cancer	5.49e-05	0.000379	CcSEcCtD
Hydralazine—Urticaria—Prednisone—prostate cancer	5.46e-05	0.000376	CcSEcCtD
Hydralazine—Pruritus—Capecitabine—prostate cancer	5.46e-05	0.000376	CcSEcCtD
Hydralazine—Leukopenia—Doxorubicin—prostate cancer	5.45e-05	0.000376	CcSEcCtD
Hydralazine—Diarrhoea—Docetaxel—prostate cancer	5.45e-05	0.000376	CcSEcCtD
Hydralazine—Body temperature increased—Prednisone—prostate cancer	5.43e-05	0.000374	CcSEcCtD
Hydralazine—Palpitations—Doxorubicin—prostate cancer	5.38e-05	0.000371	CcSEcCtD
Hydralazine—Oedema—Epirubicin—prostate cancer	5.37e-05	0.00037	CcSEcCtD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—prostate cancer	5.31e-05	0.000993	CbGpPWpGaD
Hydralazine—Diarrhoea—Capecitabine—prostate cancer	5.28e-05	0.000364	CcSEcCtD
Hydralazine—Dizziness—Docetaxel—prostate cancer	5.27e-05	0.000363	CcSEcCtD
Hydralazine—Thrombocytopenia—Epirubicin—prostate cancer	5.26e-05	0.000363	CcSEcCtD
Hydralazine—Tachycardia—Epirubicin—prostate cancer	5.24e-05	0.000362	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—EPHX1—prostate cancer	5.19e-05	0.00097	CbGpPWpGaD
Hydralazine—Myalgia—Doxorubicin—prostate cancer	5.19e-05	0.000358	CcSEcCtD
Hydralazine—Arthralgia—Doxorubicin—prostate cancer	5.19e-05	0.000358	CcSEcCtD
Hydralazine—Anxiety—Doxorubicin—prostate cancer	5.17e-05	0.000356	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—prostate cancer	5.13e-05	0.000959	CbGpPWpGaD
Hydralazine—Discomfort—Doxorubicin—prostate cancer	5.12e-05	0.000353	CcSEcCtD
Hydralazine—Anorexia—Epirubicin—prostate cancer	5.12e-05	0.000353	CcSEcCtD
Hydralazine—Dizziness—Capecitabine—prostate cancer	5.1e-05	0.000352	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C19—prostate cancer	5.07e-05	0.000948	CbGpPWpGaD
Hydralazine—Vomiting—Docetaxel—prostate cancer	5.06e-05	0.000349	CcSEcCtD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—prostate cancer	5.06e-05	0.000947	CbGpPWpGaD
Hydralazine—Hypersensitivity—Prednisone—prostate cancer	5.06e-05	0.000349	CcSEcCtD
Hydralazine—Rash—Docetaxel—prostate cancer	5.02e-05	0.000346	CcSEcCtD
Hydralazine—Hypotension—Epirubicin—prostate cancer	5.02e-05	0.000346	CcSEcCtD
Hydralazine—Dermatitis—Docetaxel—prostate cancer	5.02e-05	0.000346	CcSEcCtD
Hydralazine—Headache—Docetaxel—prostate cancer	4.99e-05	0.000344	CcSEcCtD
Hydralazine—Oedema—Doxorubicin—prostate cancer	4.97e-05	0.000343	CcSEcCtD
Hydralazine—Vomiting—Capecitabine—prostate cancer	4.9e-05	0.000338	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.89e-05	0.000337	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—prostate cancer	4.89e-05	0.000915	CbGpPWpGaD
Hydralazine—Thrombocytopenia—Doxorubicin—prostate cancer	4.87e-05	0.000336	CcSEcCtD
Hydralazine—Rash—Capecitabine—prostate cancer	4.86e-05	0.000335	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—prostate cancer	4.86e-05	0.000909	CbGpPWpGaD
Hydralazine—Pruritus—Prednisone—prostate cancer	4.86e-05	0.000335	CcSEcCtD
Hydralazine—Dermatitis—Capecitabine—prostate cancer	4.86e-05	0.000335	CcSEcCtD
Hydralazine—Tachycardia—Doxorubicin—prostate cancer	4.85e-05	0.000335	CcSEcCtD
Hydralazine—Headache—Capecitabine—prostate cancer	4.83e-05	0.000333	CcSEcCtD
Hydralazine—Paraesthesia—Epirubicin—prostate cancer	4.82e-05	0.000333	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—CYP7B1—prostate cancer	4.81e-05	0.0009	CbGpPWpGaD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—prostate cancer	4.8e-05	0.000897	CbGpPWpGaD
Hydralazine—Dyspnoea—Epirubicin—prostate cancer	4.79e-05	0.00033	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP7B1—prostate cancer	4.74e-05	0.000887	CbGpPWpGaD
Hydralazine—Anorexia—Doxorubicin—prostate cancer	4.74e-05	0.000327	CcSEcCtD
Hydralazine—Nausea—Docetaxel—prostate cancer	4.73e-05	0.000326	CcSEcCtD
Hydralazine—Dyspepsia—Epirubicin—prostate cancer	4.73e-05	0.000326	CcSEcCtD
Hydralazine—Diarrhoea—Prednisone—prostate cancer	4.7e-05	0.000324	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—SULT1E1—prostate cancer	4.69e-05	0.000877	CbGpPWpGaD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—prostate cancer	4.68e-05	0.000876	CbGpPWpGaD
Hydralazine—Decreased appetite—Epirubicin—prostate cancer	4.67e-05	0.000322	CcSEcCtD
Hydralazine—Hypotension—Doxorubicin—prostate cancer	4.65e-05	0.00032	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Epirubicin—prostate cancer	4.64e-05	0.00032	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA1—prostate cancer	4.64e-05	0.000867	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—SULT1E1—prostate cancer	4.62e-05	0.000865	CbGpPWpGaD
Hydralazine—Constipation—Epirubicin—prostate cancer	4.59e-05	0.000317	CcSEcCtD
Hydralazine—Nausea—Capecitabine—prostate cancer	4.58e-05	0.000316	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—prostate cancer	4.57e-05	0.000855	CbGpPWpGaD
Hydralazine—CYP3A4—Tryptophan metabolism—CYP1A1—prostate cancer	4.56e-05	0.000852	CbGpPWpGaD
Hydralazine—Dizziness—Prednisone—prostate cancer	4.54e-05	0.000313	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.53e-05	0.000312	CcSEcCtD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—prostate cancer	4.51e-05	0.000844	CbGpPWpGaD
Hydralazine—Paraesthesia—Doxorubicin—prostate cancer	4.46e-05	0.000308	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—NCOA2—prostate cancer	4.46e-05	0.000835	CbGpPWpGaD
Hydralazine—Dyspnoea—Doxorubicin—prostate cancer	4.43e-05	0.000306	CcSEcCtD
Hydralazine—Feeling abnormal—Epirubicin—prostate cancer	4.43e-05	0.000305	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—prostate cancer	4.41e-05	0.000825	CbGpPWpGaD
Hydralazine—Dyspepsia—Doxorubicin—prostate cancer	4.38e-05	0.000302	CcSEcCtD
Hydralazine—Vomiting—Prednisone—prostate cancer	4.37e-05	0.000301	CcSEcCtD
Hydralazine—Rash—Prednisone—prostate cancer	4.33e-05	0.000299	CcSEcCtD
Hydralazine—Dermatitis—Prednisone—prostate cancer	4.33e-05	0.000298	CcSEcCtD
Hydralazine—Decreased appetite—Doxorubicin—prostate cancer	4.32e-05	0.000298	CcSEcCtD
Hydralazine—Headache—Prednisone—prostate cancer	4.3e-05	0.000297	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.29e-05	0.000296	CcSEcCtD
Hydralazine—Urticaria—Epirubicin—prostate cancer	4.27e-05	0.000294	CcSEcCtD
Hydralazine—Constipation—Doxorubicin—prostate cancer	4.25e-05	0.000293	CcSEcCtD
Hydralazine—Body temperature increased—Epirubicin—prostate cancer	4.25e-05	0.000293	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—prostate cancer	4.16e-05	0.000778	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP3A5—prostate cancer	4.13e-05	0.000772	CbGpPWpGaD
Hydralazine—Feeling abnormal—Doxorubicin—prostate cancer	4.1e-05	0.000282	CcSEcCtD
Hydralazine—Nausea—Prednisone—prostate cancer	4.08e-05	0.000281	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP3A5—prostate cancer	4.07e-05	0.000761	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTA3—prostate cancer	3.99e-05	0.000745	CbGpPWpGaD
Hydralazine—Hypersensitivity—Epirubicin—prostate cancer	3.96e-05	0.000273	CcSEcCtD
Hydralazine—Urticaria—Doxorubicin—prostate cancer	3.95e-05	0.000272	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—prostate cancer	3.94e-05	0.000737	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTA3—prostate cancer	3.93e-05	0.000735	CbGpPWpGaD
Hydralazine—Body temperature increased—Doxorubicin—prostate cancer	3.93e-05	0.000271	CcSEcCtD
Hydralazine—Pruritus—Epirubicin—prostate cancer	3.8e-05	0.000262	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—prostate cancer	3.76e-05	0.000703	CbGpPWpGaD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—prostate cancer	3.71e-05	0.000693	CbGpPWpGaD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—prostate cancer	3.68e-05	0.000689	CbGpPWpGaD
Hydralazine—Diarrhoea—Epirubicin—prostate cancer	3.68e-05	0.000253	CcSEcCtD
Hydralazine—Hypersensitivity—Doxorubicin—prostate cancer	3.66e-05	0.000253	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—TBXAS1—prostate cancer	3.65e-05	0.000682	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTA4—prostate cancer	3.65e-05	0.000682	CbGpPWpGaD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—prostate cancer	3.64e-05	0.00068	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTA4—prostate cancer	3.6e-05	0.000672	CbGpPWpGaD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—prostate cancer	3.58e-05	0.000669	CbGpPWpGaD
Hydralazine—Dizziness—Epirubicin—prostate cancer	3.55e-05	0.000245	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—GSTA2—prostate cancer	3.55e-05	0.000664	CbGpPWpGaD
Hydralazine—Pruritus—Doxorubicin—prostate cancer	3.52e-05	0.000242	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—SULT1A1—prostate cancer	3.51e-05	0.000656	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—SULT1A1—prostate cancer	3.46e-05	0.000647	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTA1—prostate cancer	3.43e-05	0.000641	CbGpPWpGaD
Hydralazine—Vomiting—Epirubicin—prostate cancer	3.42e-05	0.000236	CcSEcCtD
Hydralazine—Diarrhoea—Doxorubicin—prostate cancer	3.4e-05	0.000235	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—NAT2—prostate cancer	3.39e-05	0.000634	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTO1—prostate cancer	3.39e-05	0.000634	CbGpPWpGaD
Hydralazine—Rash—Epirubicin—prostate cancer	3.39e-05	0.000234	CcSEcCtD
Hydralazine—Dermatitis—Epirubicin—prostate cancer	3.38e-05	0.000233	CcSEcCtD
Hydralazine—Headache—Epirubicin—prostate cancer	3.37e-05	0.000232	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTO1—prostate cancer	3.34e-05	0.000625	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—NAT2—prostate cancer	3.34e-05	0.000625	CbGpPWpGaD
Hydralazine—Dizziness—Doxorubicin—prostate cancer	3.29e-05	0.000227	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—CYP2C18—prostate cancer	3.25e-05	0.000608	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP2C18—prostate cancer	3.2e-05	0.000599	CbGpPWpGaD
Hydralazine—Nausea—Epirubicin—prostate cancer	3.19e-05	0.00022	CcSEcCtD
Hydralazine—Vomiting—Doxorubicin—prostate cancer	3.16e-05	0.000218	CcSEcCtD
Hydralazine—Rash—Doxorubicin—prostate cancer	3.13e-05	0.000216	CcSEcCtD
Hydralazine—Dermatitis—Doxorubicin—prostate cancer	3.13e-05	0.000216	CcSEcCtD
Hydralazine—Headache—Doxorubicin—prostate cancer	3.11e-05	0.000215	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—SULT2A1—prostate cancer	3.02e-05	0.000565	CbGpPWpGaD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	2.99e-05	0.000559	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—SULT2A1—prostate cancer	2.98e-05	0.000557	CbGpPWpGaD
Hydralazine—Nausea—Doxorubicin—prostate cancer	2.95e-05	0.000204	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—GPX3—prostate cancer	2.84e-05	0.000532	CbGpPWpGaD
Hydralazine—CYP3A4—Tryptophan metabolism—MDM2—prostate cancer	2.81e-05	0.000526	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—HPGDS—prostate cancer	2.71e-05	0.000507	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP2C19—prostate cancer	2.69e-05	0.000504	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP2C19—prostate cancer	2.66e-05	0.000497	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTT1—prostate cancer	2.63e-05	0.000491	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP2A6—prostate cancer	2.6e-05	0.000486	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—AKR1C3—prostate cancer	2.49e-05	0.000466	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP17A1—prostate cancer	2.49e-05	0.000465	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	2.45e-05	0.000459	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—NCOA2—prostate cancer	2.37e-05	0.000443	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	2.21e-05	0.000413	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	2.18e-05	0.000407	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	2.09e-05	0.000392	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	2.06e-05	0.000386	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GGT1—prostate cancer	2.03e-05	0.000379	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—NCOA1—prostate cancer	2e-05	0.000374	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	1.97e-05	0.000368	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	1.94e-05	0.000363	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—RXRA—prostate cancer	1.9e-05	0.000355	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—COMT—prostate cancer	1.83e-05	0.000342	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTP1—prostate cancer	1.82e-05	0.000341	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	1.8e-05	0.000338	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	1.8e-05	0.000336	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTM1—prostate cancer	1.67e-05	0.000313	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	1.65e-05	0.000309	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	1.59e-05	0.000297	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HAO1—prostate cancer	1.57e-05	0.000293	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	1.56e-05	0.000293	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ADI1—prostate cancer	1.28e-05	0.000239	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CSAD—prostate cancer	1.28e-05	0.000239	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—TST—prostate cancer	1.28e-05	0.000239	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PSAT1—prostate cancer	1.28e-05	0.000239	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GRHL1—prostate cancer	1.28e-05	0.000239	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CBR1—prostate cancer	1.28e-05	0.000239	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GRHPR—prostate cancer	1.19e-05	0.000222	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CKMT2—prostate cancer	1.19e-05	0.000222	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.19e-05	0.000222	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.19e-05	0.000222	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.12e-05	0.000209	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—AOX1—prostate cancer	1.12e-05	0.000209	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—RFK—prostate cancer	1.12e-05	0.000209	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.12e-05	0.000209	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTM3—prostate cancer	1.12e-05	0.000209	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NAGLU—prostate cancer	1.12e-05	0.000209	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PGAM2—prostate cancer	1.12e-05	0.000209	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.06e-05	0.000198	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—AMACR—prostate cancer	1.06e-05	0.000198	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—DEGS1—prostate cancer	1.06e-05	0.000198	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NAT1—prostate cancer	1.06e-05	0.000198	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.06e-05	0.000198	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.01e-05	0.000189	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—B4GALT4—prostate cancer	8.99e-06	0.000168	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HPGD—prostate cancer	8.99e-06	0.000168	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—TNFRSF21—prostate cancer	8.46e-06	0.000158	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP7B1—prostate cancer	8.23e-06	0.000154	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—MTAP—prostate cancer	8.23e-06	0.000154	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SULT1E1—prostate cancer	8.02e-06	0.00015	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SRD5A1—prostate cancer	8.02e-06	0.00015	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ACSL4—prostate cancer	7.65e-06	0.000143	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HSD17B3—prostate cancer	7.65e-06	0.000143	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—UMPS—prostate cancer	7.33e-06	0.000137	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ARG2—prostate cancer	7.33e-06	0.000137	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PHGDH—prostate cancer	7.33e-06	0.000137	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—LDHB—prostate cancer	7.19e-06	0.000134	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP3A5—prostate cancer	7.06e-06	0.000132	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PDHA1—prostate cancer	6.82e-06	0.000127	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTA3—prostate cancer	6.82e-06	0.000127	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—TCN2—prostate cancer	6.82e-06	0.000127	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—UCP3—prostate cancer	6.82e-06	0.000127	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC22A3—prostate cancer	6.5e-06	0.000122	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HSD3B1—prostate cancer	6.5e-06	0.000122	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—TBXAS1—prostate cancer	6.23e-06	0.000117	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTA4—prostate cancer	6.23e-06	0.000117	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTA2—prostate cancer	6.08e-06	0.000114	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ABCG5—prostate cancer	6e-06	0.000112	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SULT1A1—prostate cancer	6e-06	0.000112	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTA1—prostate cancer	5.86e-06	0.00011	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTO1—prostate cancer	5.8e-06	0.000108	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HSD3B2—prostate cancer	5.8e-06	0.000108	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NAT2—prostate cancer	5.8e-06	0.000108	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PLCB2—prostate cancer	5.56e-06	0.000104	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP2C18—prostate cancer	5.56e-06	0.000104	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—LRP2—prostate cancer	5.56e-06	0.000104	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—P4HB—prostate cancer	5.45e-06	0.000102	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC22A1—prostate cancer	5.3e-06	9.91e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SULT2A1—prostate cancer	5.17e-06	9.66e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—MED12—prostate cancer	5.08e-06	9.5e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GNG5—prostate cancer	5.04e-06	9.43e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NCOA3—prostate cancer	4.86e-06	9.08e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HPGDS—prostate cancer	4.63e-06	8.67e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP2C19—prostate cancer	4.6e-06	8.61e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ACHE—prostate cancer	4.49e-06	8.4e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTT1—prostate cancer	4.49e-06	8.4e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP2A6—prostate cancer	4.44e-06	8.31e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—AKR1C3—prostate cancer	4.32e-06	8.08e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PRKACB—prostate cancer	4.3e-06	8.04e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP17A1—prostate cancer	4.25e-06	7.96e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NCOA2—prostate cancer	4.05e-06	7.58e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC5A5—prostate cancer	3.87e-06	7.23e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP2E1—prostate cancer	3.78e-06	7.06e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NQO1—prostate cancer	3.73e-06	6.98e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—TH—prostate cancer	3.68e-06	6.88e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.58e-06	6.7e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GGT1—prostate cancer	3.47e-06	6.49e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NCOA1—prostate cancer	3.42e-06	6.39e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP19A1—prostate cancer	3.37e-06	6.3e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—RXRA—prostate cancer	3.25e-06	6.08e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—COMT—prostate cancer	3.13e-06	5.85e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTP1—prostate cancer	3.11e-06	5.83e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ITPR1—prostate cancer	3.06e-06	5.73e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—TYMS—prostate cancer	2.9e-06	5.42e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTM1—prostate cancer	2.86e-06	5.35e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—LPL—prostate cancer	2.81e-06	5.25e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.71e-06	5.08e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ERCC2—prostate cancer	2.69e-06	5.03e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—MTHFR—prostate cancer	2.53e-06	4.73e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PPARA—prostate cancer	2.48e-06	4.64e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CAV1—prostate cancer	2.33e-06	4.36e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.13e-06	3.98e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—INS—prostate cancer	2.01e-06	3.76e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CREBBP—prostate cancer	1.97e-06	3.69e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.87e-06	3.49e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NOS3—prostate cancer	1.76e-06	3.3e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.63e-06	3.05e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTGS2—prostate cancer	1.61e-06	3.02e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTEN—prostate cancer	1.41e-06	2.63e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—EP300—prostate cancer	1.34e-06	2.51e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CA—prostate cancer	9.93e-07	1.86e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—AKT1—prostate cancer	8.11e-07	1.52e-05	CbGpPWpGaD
